Plant-derived human butyrylcholinesterase, but not an organophosphorous- compound hydrolyzing variant thereof, protects rodents against nerve agents

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 47, 2010, Pages 20251-20256

  Geyer, Brian C ^a,d   Kannan, Latha ^a   Garnaud, Pierre Emmanuel ^a   Broomfield, Clarence A ^b   Cadieux, C Linn ^b   Cherni, Irene ^a,e   Hodgins, Sean M ^b   Kasten, Shane A ^b   Kelley, Karli ^a   Kilbourne, Jacquelyn ^a   Oliver, Zeke P ^b   Otto, Tamara C ^b   Puffenberger, Ian ^a   Reeves, Tony E ^b   Robbins II, Neil ^a   Woods, Ryan R ^a   Soreq, Hermona ^c   Lenz, David E ^b   Cerasoli, Douglas M ^b   Mor, Tsafrir S ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Countermeasures; Nonconventional warfare agents; Organophosphorous pesticides; Protein engineering; Transgenic plants

Indexed keywords

ACID ANHYDRIDE HYDROLASE; BUTYRIC ACID; BUTYRYLTHIOCHOLINE; CHOLINESTERASE; CYCLOSARIN; MACROGOL; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; PARAOXON; SARIN; SOMAN; TABUN; THIOCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL GUINEA PIG; INTOXICATION; MOUSE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; PROPHYLAXIS; TRANSGENIC PLANT;

ANIMALIA; RODENTIA;

EID: 78650558595     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009021107     Document Type: Article

References (59)

1. La Du BN, Lockridge O (1986) Molecular biology of human serum cholinesterase. Fed Proc 45:2965-2969.
2. Arpagaus M, et al. (1991) Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates. J Biol Chem 266:6966-6974.
3. Ashani Y, et al. (1991) Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 41:37-41.
4. Masson P, et al. (1998) Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta 1387:41-52.
5. Koetzner L,Woods JH (2002) Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity. Drug Metab Dispos 30:716-723.
6. McGehee DS, et al. (2000) Cholinesterase inhibition by potato glycoalkaloids slows mivacurium metabolism. Anesthesiology 93:510-519.
7. Khan SB, et al. (2005) Butyrylcholinesterase inhibitory guaianolides from Amberboa ramosa. Arch Pharmacal Res 28:172-176.
8. Loizzo MR, Tundis R, Menichini F (2008) Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: An update. Curr Med Chem 15:1209-1228.
9. DeckerM(2005) Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur J Med Chem 40:305-313.
10. Taylor P (2006) Anticholinesterase Agents. Goodman & Gilman's The Pharmacological Basis of Therapeutics, eds LL Brunton, LS Goodman, A Gilman, JS Lazo, and KL Parker (McGraw-Hill, New York), Chap 8, 11th Ed.
11. Greenfield RA, et al. (2002) Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci 323:326-340.
12. Lee EC (2003) Clinical manifestations of sarin nerve gas exposure. JAMA, J Am Med Assoc 290:659-662.
13. Cannard K (2006) The acute treatment of nerve agent exposure. J Neurol Sci 249:86-94.
14. Thiermann H, et al. (2007) Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology 233:145-154.
15. Marrs TC, Rice P, Vale JA (2006) The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 25:297-323.
16. Jokanovic M, Stukalov PV, Kosanovic M (2002) Organophosphate induced delayed polyneuropathy. Curr Drug Targets: CNS Neurol Disord 1:593-602.
17. Maxwell DM, Brecht KM, Doctor BP, Wolfe AD (1993) Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. J Pharmacol Exp Ther 264:1085-1089.
18. Ashani Y (2000) Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev Res 50:298-308.
19. Doctor BP, Saxena A (2005) Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157-158:167-171.
20. Lenz DE, et al. (2007) Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review. Toxicology 233:31-39.
21. Masson P, Lockridge O (2010) Butyrylcholinesterase for protection from organophosphorus poisons: Catalytic complexities and hysteretic behavior. Arch Biochem Biophys 494:107-120.
22. Millard CB, Lockridge O, Broomfield CA (1998) Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: Synergy results in a somanase. Biochemistry 37:237-247.
23. Millard CB, Lockridge O, Broomfield CA (1995) Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry 34:15925-15933.
24. Lockridge O, et al. (1997) A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry 36:786-795.
25. Broomfield CA, Lockridge O, Millard CB (1999) Protein engineering of a human enzyme that hydrolyzes Vand G nerve agents: Design, construction and characterization. Chem Biol Interact 119-120:413-418.
26. Huang YJ, et al. (2007) Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 104:13603-13608.
27. Platteborze PL, Broomfield CA (2000) Expression of biologically active human butyrylcholinesterase in the cabbage looper (Trichoplusia ni). Biotechnol Appl Biochem 31(Pt 3):225-229.
28. Li S, et al. (2010) High-level expression of functional recombinant human butyrylcholinesterase in silkworm larvae by Bac-to-Bac system. Chem-Biol Interact 187:101-105.
29. Evron T, et al. (2007) Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath. FASEB J 21:2961-2969.
30. Geyer BC, et al. (2007) Translational control of recombinant human acetylcholinesterase accumulation in plants. BMC Biotechnol 7:27.
31. Geyer BC, et al. (2005) Purification of transgenic plant-derived recombinant human acetylcholinesterase-R. Chem Biol Interact 157-158:331-334.
32. Geyer BC, et al. (2010) Transgenic plants as a source for the bioscavenging enzyme, humanbutyrylcholinesterase. Plant Biotechnol J, in press.
33. Kolarich D, et al. (2008) Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 8:254-263.
34. Masson P, Xie W, Froment MT, Lockridge O (2001) Effects of mutations of active site residues and amino acids interacting with the Omega loop on substrate activation of butyrylcholinesterase. Biochim Biophys Acta 1544:166-176.
35. Cohen O, et al. (2006) Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol 70:1121-1131.
36. Ashani Y, Pistinner S (2004) Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: A mathematically based toxicokinetic model. Toxicol Sci 77:358-367.
37. Cohen O, Kronman C, Lazar A, Velan B, Shafferman A (2007) Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J Biol Chem 282:35491-35501.
38. Wetherell J, Hall T, Passingham S (2002) Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 23:341-349.
39. Fischer R, Emans N (2000) Molecular farming of pharmaceutical proteins. Transgenic Res 9:279-299.
40. Mason HS, Warzecha H, Mor T, Arntzen CJ (2002) Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8:324-329.
41. Bon S, Ayon A, Leroy J, Massoulie J (2003) Trimerization domain of the collagen tail of acetylcholinesterase. Neurochem Res 28:523-535.
42. Lee HH, et al. (2004) Transcriptional regulation of acetylcholinesterase- associated collagen ColQ: Differential expression in fast and slow twitch muscle fibers is driven by distinct promoters. J Biol Chem 279:27098-27107.
43. Li H, Schopfer LM, Masson P, Lockridge O (2008) Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers. Biochem J 411:425-432.
44. Podoly E, et al. (2009) The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem 284:17170-17179.
45. Cannon MC, et al. (2008) Self-assembly of the plant cell wall requires an extensin scaffold. Proc Natl Acad Sci USA 105:2226-2231.
46. Pearce G, Siems WF, Bhattacharya R, Chen YC, Ryan CA (2007) Three hydroxyprolinerich glycopeptides derived from a single petunia polyprotein precursor activate defensin I, a pathogen defense response gene. J Biol Chem 282:17777-17784.
47. Chen YC, Siems WF, Pearce G, Ryan CA (2008) Six peptide wound signals derived from a single precursor protein in Ipomoea batatas leaves activate the expression of the defense gene sporamin. J Biol Chem 283:11469-11476.
48. Kronman C, Chitlaru T, Elhanany E, Velan B, Shafferman A (2000) Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase. J Biol Chem 275:29488-29502.
49. Cohen O, Kronman C, Velan B, Shafferman A (2004) Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta). Biochem J 378:117-128.
50. Kronman C, Cohen O, Velan B, Shafferman A (2005) Host-regulated disposition of mammalian AChEs. Chem Biol Interact 157-158:51-55.
51. Duysen EG, Bartels CF, Lockridge O (2002) Wild-Type and A328W mutant human butyrylcholinesterase tetramers expressed in chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 302:751-758.
52. Saxena A, et al. (1998) Role of oligosaccharides in the pharmacokinetics of tissuederived and genetically engineered cholinesterases. Mol Pharmacol 53:112-122.
53. Cohen O, et al. (2001) Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 357:795-802.
54. Bartling A, Worek F, Szinicz L, Thiermann H (2007) Enzyme-kinetic investigation of different sarin analogues reacting with human acetylcholinesterase and butyrylcholinesterase. Toxicology 233:166-172.
55. Jun D, Musilova L, Kuca K, Kassa J, Bajgar J (2008) Potency of several oximes to reactivate human acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon in vitro. Chem Biol Interact 175:421-424.
56. Bhat VB, Choi MH, Wishnok JS, Tannenbaum SR (2005) Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res 4:1814-1825.
57. Li B, et al. (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-1684.
58. Li B, Duysen EG, Carlson M, Lockridge O (2008) The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J Pharmacol Exp Ther 324:1146-1154.
59. Santi L, et al. (2006) Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA 103:861-866.